Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis. (August 2017)

• Record Type: Journal Article
• Authors: Masarova, Lucia; Bose, Prithviraj; Daver, Naval; Pemmaraju, Naveen; Newberry, Kate J.; Manshouri, Taghi; Cortes, Jorge; Kantarjian, Hagop M.; Verstovsek, Srdan
• Is Part Of: Leukemia research. Volume 59(2017:Aug.)
• Page Start: 110
• Page End: 116
• Publication Date: 2017-08
• Subjects: Post -- essential thrombocythemia myelofibrosis -- Post -- polycythemia vera myelofibrosis -- Primary myelofibrosis -- Prognosis; Leukemia -- Periodicals; Leukemia -- Periodicals; Leucémie -- Périodiques; Leukemia; Periodicals; Electronic journals; Electronic journals; 616.9941905
• DOI: 10.1016/j.leukres.2017.06.001
• Languages: English
• ISSNs: 0145-2126

Abstract

Highlights: Retrospective comparison of 1099 patients with primary and PET/PPV-MF myelofibrosis. Patients with PET-MF have longer overall survival than those with PPV-MF and PMF. Current prognostic scoring systems are not valid for prognostication of PET/PPV-MF. More accurate prognostic factors for PET/PPV-MF are needed. Abstract: Prognostic scoring systems for primary myelofibrosis (PMF) are not accurate in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis (PET-MF; PPV-MF). Given the paucity of data describing the clinical characteristics, disease course and outcomes of these patients, we sought to describe and compare the clinical characteristics and outcomes of 755 patients with PMF, 181 with PPV-MF, and 163 with PET-MF referred to our institution between 1984 and 2013. The median follow-up was 31 months, and 56% (n = 616) patients had died. Over an observation period of 3502 person-years, 11% of patients had progression to AML, with similar rates among groups. The proportion of patients with transfusion dependency (higher in PMF), leukocytosis and systemic symptoms (higher in PPV-MF), and thrombocytopenia (higher in PMF, PPV-MF) differed among groups. Median overall survival (OS) was longest in PET-MF patients (73 mo vs 45 mo (PMF) vs 48 mo (PPV-MF), p < 0.001). Stratification of OS by DIPSS was only discriminatory in patients with PMF, and it failed to distinguish higher risk patients with PPV/PET-MF. In multivariate analysis, predictors of inferior OS were higher age, anemia, systemic symptoms, thrombocytopenia, and high peripheral blasts in PMF; age, anemia, and systemic symptoms for PPV-MF; and anemia, peripheral blasts and thrombocytopenia in PET-MF. Although the clinical characteristics of PPV/PET-MF patients are not substantially different from those with PMF, their outcomes differ and prognostic scoring systems for PET/PPV-MF should be improved.